Pharmaids Pharmaceuticals Approves Q1 FY27 Results; TTM Revenue at Rs 28 Cr
Pharmaids Pharmaceuticals has approved its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The company is currently loss-making, with a TTM net profit of Rs -12 Cr and an operating profit margin of -48.6%. Investors should note the company's strategic shift toward the Contract Research, Development and Manufacturing Organization (CRDMO) segment to offset pricing pressures in generics. The board also approved the notice for the 37th Annual General Meeting (AGM) to be held via video conferencing.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has completed its board-level review and approval of financial performance for the first quarter of FY27.
ஏன் இது முக்கியம்For a small-cap company with a negative ROCE of -19%, quarterly results are vital to track the path toward break-even and the success of its R&D-led CRDMO strategy.
TTM வருவாய்: Rs 28 கோடிTTM Net Profit: Rs -12 Crசந்தை மதிப்பு: Rs 119 கோடிDebt-to-Equity Ratio: 0.49Promoter Holding: 32.99%
📅 குறுகிய காலம்The stock may see volatility as the market digests the specific revenue and loss figures for Q1 FY27 relative to the previous quarter's Rs 7.18 Cr revenue.
📈 நீண்ட காலம்Structural recovery depends on the company's ability to scale its CRDMO services and high-value molecules to overcome generic pricing pressures.
⚠ அபாய எச்சரிக்கைகள்
- Persistent operational losses
- Negative ROCE (-19%)
- Pricing pressure from generic competitors
- Relatively low promoter holding (33%)
👀 கவனிக்க வேண்டியவை
Review the detailed Q1 P&L to check if the operating profit margin (OPM) is improving from the -49% seen in FY26. Monitor the integration progress of recent acquisitions like Anugraha Chemicals and Spring Labs.
